[1]
|
Iwahana, H., Yanagisawa, K., Ito-Kosaka, A., Kuroiwa, K., Tago, K., Komatsu, N., Katashima, R., Itakura, M. and Tominaga, S. (1999) Different Promoter Usage and Multiple Transcription Initiation Sites of the Interleukin-1 Recep-tor-Related Human ST2 Gene in UT-7 and TM12 Cells. European Journal of Biochemistry, 264, 397-406.
https://doi.org/10.1046/j.1432-1327.1999.00615.x
|
[2]
|
Weinberg, E.O., Shimpo, M., De Keulenaer, G.W., Mac-Gillivray, C., Tominaga, S., Solomon, S.D., Rouleau, J.L. and Lee, R.T. (2002) Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction. Circulation, 106, 2961-2966. https://doi.org/10.1161/01.CIR.0000038705.69871.D9
|
[3]
|
Sanada, S., Hakuno, D., Higgins, L.J., Schreiter, E.R., McKenzie, A.N. and Lee, R.T. (2007) IL-33 and ST2 Comprise a Critical Biomechanically Induced and Cardioprotective Signaling System. Journal of Clinical Investigation, 117, 1538-1549. https://doi.org/10.1172/JCI30634
|
[4]
|
Demyanets, S., Kaun, C., Pentz, R., Krychtiuk, K.A., Rauscher, S., Pfaffenberger, S., Zuckermann, A., Aliabadi, A., Groger, M., Maurer, G., Huber, K. and Wojta, J. (2013) Components of the Interleukin-33/ST2 System Are Differentially Expressed and Regulated in Human Cardiac Cells and in Cells of the Cardiac Vasculature. Journal of Molecular and Cellular Cardiology, 60, 16-26. https://doi.org/10.1016/j.yjmcc.2013.03.020
|
[5]
|
Yancy, C.W., Jessup, M., Bozkurt, B., Masoudi, F.A., Butler, J., McBride, P.E., Casey, D.E., McMurray, J.J., Drazner, M.H., Mitchell, J.E., Fonarow, G.C., Peterson, P.N., Geraci, S.A., Horwich, T., Januzzi, J.L., Johnson, M.R., Kasper, E.K., Levy, W.C., Riegel, B., Sam, F., Stevenson, L.W., Tang, W.H., Tsai, E.J. and Wilkoff, B.L. (2013) ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 62, e147-e239. https://doi.org/10.1016/j.jacc.2013.05.019
|
[6]
|
Januzzi, J.L., Peacock, W.F., Maisel, A.S., Chae, C.U., Jesse, R.L., Baggish, A.L., O’Donoghue, M., Sakhuja, R., Chen, A.A., van Kimmenade, R.R., Lewandrowski, K.B., Lloyd-Jones, D.M. and Wu, A.H. (2007) Measurement of the Interleukin Family Member ST2 in Patients with Acute Dyspnea: Results from the PRIDE (ProBrain Natriuretic Peptide Investigation of Dyspneain the Emergency Department) Study. Journal of the American College of Cardiology, 50, 607-613. https://doi.org/10.1016/j.jacc.2007.05.014
|
[7]
|
Januzzi, J.L., Rehman, S., Mueller, T., van Kimmenade, R.R. and Lloyd-Jones, D.M. (2010) Importance of Biomarkers for Long-Term Mortality Prediction in Acutely Dyspneic Patients. Clinical Chemistry, 56, 1814-1821.
https://doi.org/10.1373/clinchem.2010.146506
|
[8]
|
Shah, R.V., Chen-Tournoux, A.A., Picard, M.H., van Kim-menade, R.R. and Januzzi, J.L. (2009) Serum Levels of the Interleukin-1 Receptor Family Member ST2, Cardiac Structure and Function, and Long-Term Mortality in Patients with Acute Dyspnea. Circulation: Heart Failure, 2, 311-319.
https://doi.org/10.1161/CIRCHEARTFAILURE.108.833707
|
[9]
|
Manzano-Fernandez, S., Mueller, T., Pascu-al-Figal, D., Truong, Q.A. and Januzzi, J.L. (2011) Usefulness of Soluble Concentrations of Interleukin Family Member ST2 as Predictor of Mortality in Patients with Acutely Decompensated Heart Failure Relative to Left Ventricular Ejection Fraction. American Journal of Cardiology, 107, 259-267.
https://doi.org/10.1016/j.amjcard.2010.09.011
|
[10]
|
Rehman, S.U., Mueller, T. and Januzzi, J.L. (2008) Charac-teristics of the Novel Interleukin Family Biomarker ST2 in Patients with Acute Heart Failure. JACC: Journal of the American College of Cardiology, 52, 1458-1465.
https://doi.org/10.1016/j.jacc.2008.07.042
|
[11]
|
Pascual-Figal, D.A., Manzano-Fernandez, S., Boronat, M., Casas, T., Garrido, I.P., Bonaque, J.C., Pastor-Perez, F., Valdes, M. and Januzzi, J.L. (2011) Soluble ST2, High-Sensitivity, Troponin-T and N-Terminal pro-B-type Natriuretic Peptide, Complementary Role for Risk Stratification in Acutely Decompensated Heart Failure. European Journal of Heart Failure, 13, 718-725. https://doi.org/10.1093/eurjhf/hfr047
|
[12]
|
Lassus, J., Gayat, E., Mueller, C., Peacock, W.F., Spinar, J., Harjola, V.P., van Kimmenade, R., Pathak, A., Mueller, T., Disomma, S., Metra, M., Pascual-Figal, D., Laribi, S., Logeart, D., Nouira, S., Sato, N., Potocki, M., Parenica, J., Collet, C., Cohen-Solal, A., Januzzi, J.L. and Mebazaa, A. (2013) In-cremental Value of Biomarkers to Clinical Variables for Mortality Prediction in Acutely Decompensated Heart Failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) Study. International Journal of Cardiology, 168, 2186-2194.
https://doi.org/10.1016/j.ijcard.2013.01.228
|
[13]
|
Zilinski, J.L., Shah, R.V., Gaggin, H.K., Gantzer, M.L., Wang, T.J. and Januzzi, J.L. (2012) Measurement of Multiple Biomarkers in Advanced Stage Heart Failure Patients Treated with Pulmonary Artery Catheter Guided Therapy. Critical Care, 16, r135. https://doi.org/10.1186/cc11440
|
[14]
|
Boisot, S., Beede, J., Isakson, S., Chiu, A., Clopton, P., Januzzi, J., Maisel, A.S. and Fitzgerald, R.L. (2008) Serial Sampling of ST2 Predicts 90-Day Mortality Following Destabilized Heart Failure. Journal of Cardiac Failure, 14, 732-738. https://doi.org/10.1016/j.cardfail.2008.06.415
|
[15]
|
Manzano-Fernandez, S., Januzzi, J.L., Pastor-Perez, F.J., Bonaque-Gonzalez, J.C., Boronat-Garcia, M., Pascual-Figal, D.A., Montalban-Larrea, S., Navarro-Penalver, M., An-dreu-Cayuelas, J.M. and Valdes, M. (2012) Serial Monitoring of Soluble Interleukin Family Member ST2 in Patients with Acutely Decompensated Heart Failure. Cardiology, 122, 158-166. https://doi.org/10.1159/000338800
|
[16]
|
Ky, B., French, B., McCloskey, K., Rame, J.E., McIntosh, E., Shahi, P., Dries, D.L., Tang, W.H., Wu, A.H., Fang, J.C., Boxer, R., Sweitzer, N.K., Levy, W.C., Goldberg, L.R., Jessup, M. and Cappola, T.P. (2011) High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure. Circulation: Heart Failure, 4, 180-187.
https://doi.org/10.1161/CIRCHEARTFAILURE.110.958223
|
[17]
|
Bayes-Genis, A., de Antonio, M., Vila, J., Penafiel, J., Galan, A., Barallat, J., Zamora, E., Urrutia, A. and Lupon, J. (2014) Head-to-Head Comparison of 2 Myo-cardial Fibrosis Biomarkers for Long-Term Heart Failure Risk Stratification: ST2 versus Galectin-3. Journal of the American College of Cardiology, 63, 158-166.
https://doi.org/10.1016/j.jacc.2013.07.087
|
[18]
|
Gaggin, H.K., Szymonifka, J., Bhardwaj, A., Belcher, A., De Berardinis, B., Motiwala, S., Wang, T.J. and Januzzi, J.L. (2014) Head-to-Head Comparison of Serial Soluble ST2, Growth Differentiation Factor-15, and Highly-Sensitive Troponin T Measurements in Patients with Chronic Heart Failure. JACC Heart Fail, 2, 65-72.
https://doi.org/10.1016/j.jchf.2013.10.005
|
[19]
|
Gaggin, H.K., Motiwala, S., Bhardwaj, A., Parks, K.A. and Januzzi, J.L. (2013) Soluble Concentrations of the Interleukin Receptor Family Member ST2 and Beta-Blocker Therapy in Chronic Heart Failure. Circulation: Heart Failure, 6, 1206-1213. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000457
|
[20]
|
Anand, I.S., Rector, T.S., Kuskowski, M., Snider, J. and Cohn, J.N. (2014) Prognostic Value of Soluble ST2 in the Valsartan Heart Failure Trial. Circulation: Heart Failure, 7, 418-426.
https://doi.org/10.1161/CIRCHEARTFAILURE.113.001036
|